当社は2004年に当社CEOであるJames Ryanと当社取締役であるDr. Naresh Trehan 、Yury Verlinskyのが共同で設立した幹細胞移植治療会社が前身となります。
その後、Alan Russell、Masashi Komeda..、Alan W. Schoenbart / Mel Silberklangが加わりI-Horus Inc.として生まれ変わりました。
Standing on the right hand side (to my left) is Dr. Yury Verlinsky, a scientist whom I have the greatest respect for, and giant who made enormous scientific discoveries for humanity, and had a tremendous influence on me and of my responsibility to progress stem cells sciences in our short lifetime.
The road that led to the forming of iHorus and AppliCell was built by his influence, by his inspiration, and fierce passion for scientific progress. Because of him thousands of healthy children are alive and many more will be born healthy without suffering all their precious little lives from a devastating genetic diseases.
Dr. Yury Verlinsky surpisingly does not have a Noble Prize, and sadly he has passed away. But his towering scientific intelligence, and logic has led me to be here on this journey.
This stem cell journey started over 12 years ago when one of Dr. Yury Verlinskys inventions saved the life of a dying boy who was suffering from deadly genetic disease called Fanconi Anemia, his invention enabled the creation of exact (HLA) genetic matched hematopoietic stem cells that saved the childs life.
Because of Dr. Yury Verlinsky I have continued to progress, to believe that I will help my son whose life is dependent on a life support system, who has fought 15 years waiting.
I am here standing on the shoulder of a giant named Yury, and I can never show how grateful I am to him. Dr. Yury Verlinsky will always be our Honorary Chairman of Science
Chief Financial Officer （Elected)
Mr. Schoenbart was named the Chief Executive Officer in May'2008. Prior to joining Forticell, Mr. Schoenbart was the Chief Financial Officer of Vizacom
Inc., a publicly traded provider of software, diverse information technology services and products, and designer of WiFi networks. He has extensive experience in SEC reporting, budgeting,
forecasting, stocks and debt offerings, investor relations, accounting and internal control systems, as well as administrative and operational expertise.
Mr. Schoenbart has a BS in accounting and is a Certified Public Accountant in New York.
Chief Scientific Officer
From 1981 to 1993, Dr. Silberklang worked for the Merck Research Laboratories in Rahway, New Jersey, initially in gene cloning and expression, and recombinant gene-derived
protein production, and later in cell culture process scale-up and research and development. From 1988 to 1993 Dr. Silberklang was Associate Director of Cell and Molecular Biology, in which
capacity he directed development of scaleable cell culture processes and produced cells, viruses (for vaccines) and recombinant proteins for preclinical and clinical uses. From 1993 to 1995, Dr.
Silberklang was Senior Director of Process Research and Development at Enzon, Inc., where he developed and implemented a bioreactor process for baculovirus-directed production of recombinant
Glucocerebrosidase for a clinical trial.
Since 1995, Dr. Silberklang has worked for Forticell International, Inc. and is responsible for basic and applied research, including bioprocess development and pilot production of a human cultured skin product for clinical trials. He has worked and published extensively in the areas of cell culture medium development, cell culture process research and development, and bioreactor process design.
Dr. Silberklang obtained his Ph.D. in biochemistry from M.I.T. in 1977, and did postdoctoral work in Drosophila molecular genetics and cell biology at the University of California at San Francisco.
Registered office is located at: 16192 Coastal Highway,
Lewies, State of Delaware 19958-9776, County of Sussex
The United States of America
333 Sylvan Ave., Suite 101
Englewood Cliffs, NJ 07632
The United States of America